Table 2.
Clinical, radiological, and histological characteristics of the patients with DIPG from our cohort.
| Patient ID | Sex | Status | Age at diagnosis | Treatment | Available histology | Histological diagnosis | Time to progression | Overall survival | CN V diagnosis | CN V follow-up | Tumor size | Ring enhancement | Dissemination at follow up | Scanner | Slice thickness |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M | DOD | 81 | B | No | n/a | 14 | 18 | No | no | 2,000 | No | Yes | 3 T | 3 mm |
| 2 | M | DOD | 54 | A | No | n/a | 2 | 4 | Yes | Yes | 1,768 | No | Yes | 3 T | 3 mm |
| 3 | M | DOD | 100 | A | No | n/a | 3 | 5 | No | No | 1,116 | No | No | 1.5 T | 4 mm |
| 4 | F | DOD | 57 | A | No | n/a | 3 | 10 | No | No | 851 | No | No | 1.5 T | 4 mm |
| 5 | F | DOD | 112 | B | Yes | Diffuse midline glioma, H3K27M mutant | 11 | 20 | No | No | 1,845 | Yes | No | 3 T | 3 mm |
| 6 | M | DOD | 51 | A | No | n/a | 3 | 7 | Yes | No | 1,925 | No | No | 1.5 T | 4 mm |
| 7 | M | DOD | 154 | B | Yes | Diffuse midline glioma, H3K27M mutant | 7 | 8 | No | No | 999 | No | No | 3 T | 3 mm |
| 9 | M | DOD | 61 | B | No | n/a | 9 | 13 | No | No | 1,344 | No | No | 3 T | 3 mm |
| 10 | F | LAF | 166 | B | Yes | Diffuse midline glioma, H3K27M mutant | 6 | 6 | No | No | 1,000 | No | No | 3 T | 3 mm |
| 11 | F | DOD | 49 | B | No | n/a | 7 | 14 | No | No | 1,739 | No | No | 3 T | 3 mm |
| 12 | F | DOD | 50 | A | No | n/a | 7 | 13 | No | No | 1,344 | No | No | 1.5 T | 4 mm |
| 13 | M | DOD | 76 | A | No | n/a | 8 | 10 | No | No | 1,462 | Yes | No | 1.5 T | 4 mm |
| 14 | M | DOD | 51 | B | No | n/a | 5 | 8 | No | No | 1,152 | No | Yes | 3 T | 3 mm |
| 17 | M | DOD | 81 | A | No | n/a | 7 | 16 | No | No | 2,552 | No | Yes | 1.5 T | 4 mm |
| 18 | F | DOD | 46 | B | No | n/a | 3 | 7 | No | No | 2,160 | No | No | 3 T | 3 mm |
| 19 | F | DOD | 36 | A | No | n/a | 4 | 10 | Yes | Yes | 1,764 | Yes | No | 1.5 T | 4 mm |
| 20 | F | DOD | 49 | B | No | n/a | 2 | 3 | No | No | 1,161 | No | No | 3 T | 3 mm |
| 21 | M | DOD | 72 | B | No | n/a | 8 | 7 | No | No | 2,262 | Yes | No | 3 T | 3 mm |
| 22 | F | DOD | 81 | B | Yes | Diffuse midline glioma, H3K27M mutant | 7 | 9 | No | No | 850 | No | No | 3 T | 3 mm |
| 23 | F | DOD | 51 | A | No | n/a | 4 | 23 | No | No | 1,800 | Yes | No | 1.5 T | 4 mm |
| 25 | M | DOD | 173 | B | No | n/a | 8 | 12 | No | No | 1,364 | No | No | 3 T | 3 mm |
| 27 | M | DOD | 67 | B | Yes | Diffuse midline glioma, H3K27M mutant | 8 | 12 | Yes | No | 1,824 | No | Yes | 3 T | 3 mm |
| 29 | F | DOD | 68 | B | Yes | Diffuse midline glioma, H3K27M mutant | 8 | 11 | No | No | 1,102 | Yes | No | 3 T | 3 mm |
| 30 | M | AWD | 73 | B | Yes | Diffuse midline glioma, H3K27M mutant | 5 | 15 | No | No | 1,736 | Yes | No | 3 T | 3 mm |
| 31 | F | DOD | 79 | B | Yes | Diffuse midline glioma, H3K27M mutant | 3 | 15 | No | No | 1,575 | No | No | 3 T | 3 mm |
| 32 | M | DOD | 65 | B | Yes | Diffuse midline glioma, H3K27M mutant | 6 | 13 | No | No | 2,200 | Yes | No | 3 T | 3 mm |
| 33 | F | AWD | 111 | B | Yes | Diffuse midline glioma, H3K27M mutant | 6 | 13 | No | No | 1,519 | Yes | No | 3 T | 3 mm |
| 34 | F | AWD | 30 | B | Yes | Diffuse midline glioma, H3K27M mutant | 18 | 18 | No | No | 1,980 | No | No | 3 T | 3 mm |
| 35 | M | DOD | 72 | B | Yes | Diffuse midline glioma, H3K27M mutant | 7 | 8 | No | No | 1,833 | No | No | 3 T | 3 mm |
ID, patient number; sex, male (M) or female (F); Status, patient outcome including alive with disease (AWD), dead of disease (DOD) or lost at follow-up (LAF); Age at diagnosis, age at diagnosis expressed in months; Treatment, patient first line of treatment with radiotherapy and Temozolomide (A) or with radiotherapy, Nimotuzumab and Vinorelbine (B); Available histology, available (yes) or non-available (no) histological diagnosis, according to the WHO 2016 classification; Histological diagnosis, diffuse midline glioma, H3K27M mutant, according to the WHO 2016 or n/a, not available; Time to progression, the length of time from the date of diagnosis of DIPG until the radiological and/or clinical progression of the disease, expressed in months; Overall survival, overall survival expressed in months; CN V diagnosis, direct cranial nerve V involvement at diagnosis present (yes) or absent (no); CN V follow-up, direct cranial nerve V involvement at follow-up present (yes) or absent (no); Tumor size, tumor size expressed in mm2; Ring enhancement, ring enhancement present (yes) or absent (no) at diagnosis; Dissemination at follow-up, distant localization of the tumor present (yes) or absent (no) on the follow-up scans; Scanner, magnet strength, expressed as 3 Tesla (3 T) or 1.5 Tesla (1.5 T); Slice thickness, slice thickness of the sequences contained in the imaging protocol, respectively 3 millimeters (3 mm) or 4 millimeters(4 mm).